Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy
Han J, Dong Y, Zhu X, Reuben A, Zhang J, Xu J, Bai H, Duan J, Wan R, Zhao J, Bai J, Xia X, Yi X, Cheng C, Wang J, Wang Z. Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy. Nature Communications 2024, 15: 1199. PMID: 38331912, PMCID: PMC10853168, DOI: 10.1038/s41467-024-45361-5.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsHLA-INeoantigen presentationPresentation capacityPatients treated with immune checkpoint inhibitorsHuman leukocyte antigen class IICI responseImmune checkpoint inhibitor treatmentResponse to immunotherapyAntigen presentation capacityAntigen presentation pathwayCheckpoint inhibitorsSurvival benefitNeoantigen productionTumor microenvironmentCancer patientsPresentation pathwayClinical utilityClass IPatientsTumorPresentationPresentation scoreScoresImmunotherapy